Associated Papers
DA-Raf synergistically binds to the plasma membrane and Ras to suppress ERK signaling.
Takano K et al.
Life Science Alliance, 2025
Proteome-scale characterisation of motif-based interactome rewiring by disease mutations.
Kliche J et al.
Molecular Systems Biology, 2024
[Mutation pedigree and treatment selection of Erdheim-Chester disease].
Lang M et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.
Durham BH et al.
Nature Medicine, 2019
ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.
Li D et al.
Nature Medicine, 2019
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
Jones GG et al.
Nature Communications, 2019
Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers.
Heim D et al.
Genome Medicine, 2018
The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort.
Ozkaya N et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2018
Three Cases of Erdheim-Chester Disease With Intraocular Manifestations: Imaging and Histopathology Findings of a Rare Entity.
Tan ACS et al.
American Journal of Ophthalmology, 2017
Histiocytic neoplasms in the era of personalized genomic medicine.
Durham BH et al.
Current Opinion in Hematology, 2016
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL et al.
Cancer Discovery, 2016
Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.
Sia D et al.
Nature Communications, 2015
A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity.
Rodriguez-Viciana P et al.
Molecular Cell, 2006